Percutaneous Treatment of the Tricuspid Valve Disease: New Hope for the “Forgotten” Valve

Campelo‐Parada, Francisco; Lairez, Olivier; Carrié, Didier

doi:10.1016/j.rec.2017.05.010

Cited by 8 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…All TVRs at our center were performed using a conventional open surgical approach. Novel transcatheter approaches in the treatment of TR are currently being developed, and some have successfully been implanted in humans [23], representing a potentially viable alternative to open TVR, and a modality for re-intervention after failed TVR. A multi-center French study has reported successful tricuspid valve-in-valve implantation of the Melody (Medtronic, Minneapolis, MN) and SA-PIEN (Edwards Lifesciences, Irvine, CA) transcatheter valves in high-risk patients with failing tricuspid bioprostheses [24].…”

Section: Discussionmentioning

confidence: 99%

Isolated Tricuspid Valve Replacement for Infective Endocarditis

et al. 2022

View full text Add to dashboard Cite

Background: Existing data regarding isolated tricuspid valve replacement for primary tricuspid valve disease such as infective endocarditis (IE) are limited. The aim of this study was to review our experience of isolated tricuspid valve replacement for IE. Methods:A retrospective review was performed to evaluate the perioperative and long-term outcomes of patients undergoing isolated tricuspid valve replacement for IE at our tertiary referral center between January 2000 and December 2014. Surgical outcomes were reviewed to include survival and postoperative complications.Results: Seven patients underwent isolated tricuspid valve replacement for IE during the study period. Mean age was 41 ± 14 years with six (86%) males. Six patients (86%) were intravenous drug users. Five patients (71%) presented with septic emboli to the lungs. Five patients (71%) had active endocarditis at the time of surgery. The indications for surgery were heart failure in three patients (43%), persistent sepsis in three patients (43%) and both in one patient (14%). Methicillin-sensitive Staphylococcus aureus was the most common infective organism, isolated in five patients (71%). There were no in-hospital mortalities or permanent pacemaker implantations. Follow-up was completed in 86% of the cases. The median follow-up period was 13 months (range 2 to 129 months). Three patients (43%) died during the follow-up period, at 7 months, 8 months and 13 months, respectively. All deaths were associated with prosthetic valve IE and recurrent intravenous drug use. Conclusions:This study supplements the paucity of data pertaining to tricuspid valve replacement for IE in the local population. Survival outcomes can be improved with prompt surgical intervention, optimal medical optimization, and a holistic, psychosocial approach targeting intravenous drug abuse.

show abstract

Section: Discussionmentioning

confidence: 99%

Isolated Tricuspid Valve Replacement for Infective Endocarditis

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Tricuspid valve surgery has been suggested to be associated with poor outcomes [Itzhaki 2019]. When a reoperative tricuspid valve replacement is performed, the risk of mortality greatly increases [Abu Sham'a 2013;Hamandi 2019;Campelo-Parada 2017]. However, it also should be pointed out that these results have many confounding factors.…”

Section: Introductionmentioning

confidence: 99%

The Risk and Outcomes of Reoperative Tricuspid Valve Replacement Surgery

Chen

et al. 2020

HSF

View full text Add to dashboard Cite

Objectives: Functional tricuspid regurgitation (TR) usually occurs with previous cardiovascular surgery, which causes right-side heart failure and affects patient prognosis. Thus, we aimed to assess the risk and outcomes of isolated tricuspid valve replacement (TVR) after cardiovascular surgery. Methods: We reviewed our hospital medical records and found 107 patients, who had undergone TVR following cardiovascular surgery from June 2009 to November 2017. Follow up was performed by telephone calls, with a mean follow up of 51 months (one to 120 months). Previous surgical procedures of all patients were recorded, and we compared the differences in baseline and preoperative characteristics between the survival and non-survival groups by univariate analysis. Furthermore, logistic regression analysis was performed to identify the risk factors. The variables with a P value < .05 on univariate analysis were entered into a multivariate analysis using stepwise selection. Results: TVR was performed in 107 patients, including 89 survivors and 18 non-survivors during the follow up. There were 38 male and 69 female patients, and the mean age was 53.55 years. Hospital mortality was 16.8% (18/107). The APACHE II (P < .001) and mechanical ventilation time (P = .001) were higher in the non-survival group. The values of B-type natriuretic peptide (BNP), total bilirubin (TB), and blood urea nitrogen (BUN) before and after the operation and some preoperative values were different between the two groups (P < .05). The logistic regression analysis showed that APACHE II score, mechanical ventilation time, preoperative albumin, and postoperative TB were risk factors for TVR after cardiovascular surgery. Conclusions: Reoperation tricuspid valve replacement is associated with high operative mortality. High APACHE II scores, mechanical ventilation time and postoperative TB were associated with increased short-term mortality risk, while high preoperative albumin levels decreased the risk. Positive reoperation for tricuspid valve prosthesis dysfunction can obtain satisfactory therapeutic effects, and survivors could benefit from the surgery.

show abstract